药品“身份证”重塑医保基金监管生态系统

Core Insights - The application of drug traceability codes is transforming the regulatory ecosystem of medical insurance funds, enhancing transparency and accountability in the pharmaceutical sector [1][3][5] Group 1: Regulatory Developments - As of March 31, 2025, the National Medical Insurance Information Platform has accumulated 27.309 billion traceability codes, covering 31 provinces and regions, with 88.9 thousand designated hospitals and pharmacies connected, representing 95.6% of total designated medical institutions [1] - The integration of over 95% of medical insurance drug transaction data into real-time supervision marks a significant shift from traditional regulatory models, addressing previous "information blind spots" [1][3] Group 2: Technological Advancements - The drug traceability code functions as a "digital ID" for pharmaceuticals, providing comprehensive tracking capabilities that include production details and expiration dates, thus curbing illegal practices [3][5] - The daily access to the traceability query function has surpassed 500,000 visits, indicating a growing public engagement in monitoring drug safety [3] Group 3: Impact on Stakeholders - The increasing connection rate of medical institutions and pharmaceutical companies is driving improvements in internal management systems and digital management capabilities [5] - The traceability feature not only ensures medication safety for insured individuals but also enhances their awareness as stakeholders in the medical insurance fund [5] Group 4: Future Prospects - The regulatory framework is evolving from reactive measures to proactive prevention, supported by real-time monitoring and intelligent risk alerts [5] - The potential expansion of digital regulation, including innovations like "electronic medical insurance IDs" and "AI assessments of medical behaviors," promises to cover all aspects of medical services [5]